Recent declines in breast cancer incidence: Mounting evidence that reduced use of menopausal hormones is largely responsible

Breast Cancer Research

Volumn 12, Issue 1, 2010, Pages

  Banks, Emily ^a   Canfell, Karen ^b,c  

^a The Australian National University   (Australia)

^b CANCER RESEARCH DIVISION   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; EDITORIAL; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENOPAUSE; WOMEN'S HEALTH; BREAST TUMOR; ESTROGEN THERAPY; FEMALE; INCIDENCE; NOTE; TIME; UNITED STATES;

BREAST NEOPLASMS; CALIFORNIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; TIME FACTORS;

EID: 77956027867     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2463     Document Type: Editorial

References (15)

1. Marshall SF, Clarke CA, Deapen D, DeLellis Henderson K, Largent J, Neuhausen SL, Reynolds P, Ursin G, Horn-Ross PL, Stram DO, Templeman C, Bernstein L. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 2010, 12:R4. 10.1186/bcr2467, 20064209, 2880422.
2. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007, 356:1670-1674. 10.1056/NEJMsr070105, 17442911.
3. Canfell K, Banks E, Moa A, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008, 188:641-644.
4. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008, 372:608-610. 10.1016/S0140-6736(08)61255-6, 18722851.
5. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative Investigators.
6. Medicines and Healthcare Products Regulatory Agency UK Public Assessment Report. Hormone-replacement therapy: safety update 2007, London: Medicines and Healthcare Products Regulatory Agency, Medicines and Healthcare Products Regulatory Agency., http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2032228.pdf
7. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997, 350:1047-1059. 10.1016/S0140-6736(97)08233-0, 10213546, Collaborative Group on Hormonal Factors in Breast Cancer.
8. Million Women Study Collaborators Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003, 362:419-427. 10.1016/S0140-6736(03)14065-2, 12927427, Million Women Study Collaborators.
9. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G, . WHI Investigators Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587. 10.1056/NEJMoa0807684, 19196674, WHI Investigators.
10. Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2008, 17:3150-3160. 2755180, 18990757, 10.1158/1055-9965.EPI-08-0435.
11. Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Møller S, Rank F, Ottesen B, Lynge E. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 2004, 91:644-650. 2364797, 15238982.
12. Austin DF, Roe FJ. The decreasing incidence of endometrial cancer: public health implications. Am J Public Health 1982, 72:65-68. 1649756, 7053625, 10.2105/AJPH.72.1.65.
13. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000, 321:323-329. 27446, 10926586, 10.1136/bmj.321.7257.323.
14. Banks E, Canfell K. Invited commentary: hormone therapy risks and benefits--the Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 2009, 170:24-28. 10.1093/aje/kwp113, 19468078.
15. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE. Benefits and risks of postmenopausal hormone therapy when initiated soon after then menopause. Am J Epidemiol 2009, 170:12-23. 10.1093/aje/kwp115, 19468079, 2733042.